LIORESAL by Novartis is clinical pharmacology the precise mechanism of action of baclofen as a muscle relaxant and antispasticity agent is not fully understood. First approved in 1977.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
LIORESAL (baclofen) is an oral small-molecule muscle relaxant and antispasticity agent approved in 1977 that works by inhibiting monosynaptic and polysynaptic reflexes at the spinal level, likely through GABA-B receptor stimulation. It is used to reduce muscle spasms and spasticity associated with conditions such as spinal cord injury, cerebral palsy, and multiple sclerosis. Baclofen decreases excitatory neurotransmitter release from primary afferent terminals, producing CNS depressant effects including sedation and muscle relaxation.
Product is in late-stage lifecycle with approaching loss of exclusivity; expect gradual team contraction and shift toward generic/lifecycle management strategies.
CLINICAL PHARMACOLOGY The precise mechanism of action of baclofen as a muscle relaxant and antispasticity agent is not fully understood. Baclofen inhibits both monosynaptic and polysynaptic reflexes at the spinal level, possibly by decreasing excitatory neurotransmitter release from primary…
Worked on LIORESAL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on LIORESAL offers stable, legacy-product experience in a mature therapeutic area with limited growth potential. Professionals should expect focus on maintaining market share, managing generic competition, and optimizing operational efficiency rather than driving expansion.